Skip Navigation


Brain Advance Access originally published online on September 29, 2005
Brain 2005 128(12):2933-2940; doi:10.1093/brain/awh646
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/12/2933    most recent
awh646v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Appenzeller, S.
Right arrow Articles by Cendes, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Appenzeller, S.
Right arrow Articles by Cendes, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study

Simone Appenzeller1,3, Li Min Li2,3, Lilian T. L. Costallat1 and Fernando Cendes2,3

1 Departments of Rheumatology and 2 Neurology and 3 Neuroimaging Laboratory, University of Campinas, São Paulo, Brazil

Correspondence to: Dr Fernando Cendes, MD, PhD, Department of Neurology, FCM–UNICAMP, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, Brazil, CEP 13083-970 E-mail: fcendes{at}unicamp.br

Our objective was to investigate axonal dysfunction in patients with systemic lupus erythematosus (SLE) using proton magnetic resonance spectroscopy (1H-MRS).We studied prospectively 90 SLE patients (mean age of 32.5 years) and 23 normal volunteers (mean age of 33.8 years). We performed single voxel proton MRS using point resolved spectroscopy sequence over the superior–posterior region of the corpus callosum. We measured signals from N-acetyl compounds [N-acetylaspartate (NAA)] at 2.01 p.p.m., choline-based compounds (Cho) at 3.2 p.p.m. and creatine and phosphocreatine containing compounds (Cr) at 3.0 p.p.m. and determined NAA/Cr ratios. After 12 months, MRI and MRS were repeated in 50 patients and 9 volunteers. Patients were divided according to disease activity (measured by SLE disease activity index) during initial and follow-up MRS. We performed paired t-test and ANOVA with Tukey's post hoc comparisons to evaluate group differences. At study entry, 29 patients had active SLE with involvement of central nervous system (CNS) and 28 patients had active SLE without CNS manifestations. A total of 14 patients had inactive SLE with past CNS presentation, and 19 had inactive SLE without history of CNS involvement. NAA/Cr ratios were significant lower in patients with active SLE, independently of CNS involvement, when compared with patients with inactive SLE (P = 0.005) and controls (P = 0.01). We observed a significant increase in NAA/Cr ratio in 15 patients who had active SLE at initial MRS and inactive SLE at follow-up (P = 0.04). In 10 patients with active SLE both at initial and at follow-up MRS we observed a reduction in NAA/Cr ratio (P = 0.02). By contrast, there was a significant reduction of NAA/Cr ratio in 15 patients who had inactive SLE at initial MRS and active SLE at follow-up (P = 0.001). In 10 patients with inactive SLE both at initial and at follow-up MRS NAA/Cr ratio did not change (P = 0.2). This study shows evidence of axonal dysfunction in patients with active SLE, independently of CNS manifestations that may be reversible, at least in part, during periods of inactivity of disease.

Key Words: axonal dysfunction; magnetic resonance spectroscopy; N-acetylaspartate; systemic lupus erythematosus

Abbreviations: ACR = American College of Rheumatology; Cho = choline-based compounds; CNS = central nervous system; Cr = creatine and phosphocreatine containing compounds; LA = lupus anticoagulant; MRS = magnetic resonance spectroscopy; NAA = N-acetylaspartate; PRESS = point resolved spectroscopy; 1H-MRS = proton magnetic spectroscopy; ROI = region of interest; SLE = systemic lupus erythematosus; SLEDAI = SLE disease activity index

Received April 26, 2005. Revised August 20, 2005. Accepted August 30, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
LupusHome page
S. Appenzeller, L.M. Li, L.T.L. Costallat, and F. Cendes
Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus
Lupus, December 1, 2007; 16(12): 963 - 971.
[Abstract] [PDF]


Home page
BrainHome page
M.-T. Tseng, S.-C. Hsieh, C.-T. Shun, K.-L. Lee, C.-L. Pan, W.-M. Lin, Y.-H. Lin, C.-L. Yu, and S.-T. Hsieh
Skin denervation and cutaneous vasculitis in systemic lupus erythematosus
Brain, April 1, 2006; 129(4): 977 - 985.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.